Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment

BMC Complementary and Alternative Medicine

Research Article

Lucas Luis Colombo¹  Aline Tansini²  Lívia Carolina Abreu de Ribeiro²  Lucas Souza Ferreira²  Marisa Campos Polesi Placeres²  Djamile Cordeiro de Matos²  Iracilda Zeppone Carlos³ 

[1] Institute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina;Laboratory of Clinical Immunology, School of Pharmaceutical Sciences, São Paulo State University, São Paulo, Brazil;Laboratory of Clinical Immunology, School of Pharmaceutical Sciences, São Paulo State University, São Paulo, Brazil;Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Rua Expedicionários do Brasil 1601, 14801-902, Araraquara, SP, Brazil;

关键词: Pulchellin;    Breast cancer;    Cytokines;    Immune system;   

DOI  :  10.1186/1472-6882-12-107

 received in 2012-03-29, accepted in 2012-07-11,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundRibosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.MethodsThe percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines’ release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test.ResultsPulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in macrophage’s activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).ConclusionsOur results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.

【 授权许可】

Unknown   
© de Matos et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.